Author

Shuo Qian

Simcere Pharmaceutical (China)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Chunxia Ao· 1 shared Feng ZhouiD· 1 shared Gang Liu· 1 shared Jiajia LiiD· 1 shared Jing DaiiD· 1 shared Lei JiangiD· 1 shared Li ZhouiD· 1 shared Liting XueiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Chunxia Ao

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ZMS-6659, a selective Polθ helicase inhibitor, demonstrates anti-tumor activity as monotherapy and synergy effect with PARP inhibitors and topoisomerase inhibitors

Lei Jiang, Jiajia Li, Lu Liu, Mengying Li, Wenjing Li, Zhen Li, Shuo Qian, Mingyue Shi, Jing Dai, Chunxia Ao, Ying Qu, Zhengtao Li, Li Zhou, Yang Chen, Xiyuan Wang, , Liting Xue

ZMS-6659, a Polθ helicase inhibitor, shows anti-tumor activity as monotherapy and synergizes with PARP inhibitors and topoisomerase inhibitors in HR-deficient and HR-proficient models.

bioRxiv · Apr 19, 2025 · PreprintCancer Biology